New hope for transplant patients: drug aims to block dangerous virus without harsh side effects
NCT ID NCT05370976
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 29 times
Summary
This study tested a medicine called Cytotect to prevent cytomegalovirus (CMV) infection in people who had a stem cell transplant and then developed graft-versus-host disease (GVHD). CMV is a common virus that can be very dangerous for these patients. The goal was to see if Cytotect could lower the risk of CMV infection without the severe side effects of standard antiviral drugs. The study was stopped early after enrolling only 2 participants, so results are very limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS INFECTIONS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hop Claude Huriez Chu Lille
Lille, France
Conditions
Explore the condition pages connected to this study.